Skip to Content

Insulet Corp PODD Stock Quote

| Rating as of

Morningstar‘s Stock Analysis PODD

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Insulet Accelerates U.S. Growth and Operating Expenses in Q2; No Change to Our Fair Value Estimate

Debbie S. Wang Senior Equity Analyst

Analyst Note

| Debbie S. Wang |

Insulet's second-quarter performance demonstrated strength on the top line in the United States as the new Omnipod 5 enters full commercial launch, but a significant jump in operational expense startled us. Overall, the two factors were largely a wash, and we’re leaving our fair value estimate unchanged. We remain confident in Insulet’s narrow economic moat, which is supported by intangible assets as we see this firm accelerate its innovation. Though Insulet was not the first to introduce the hybrid closed loop, it did manage to develop and launch its new pump with comparable functionality within a reasonable period of time. The firm was also the recipient of a lucky break when Medtronic ran into regulatory issues with its 670G pump, which has delayed U.S. approval of its next-generation 780G.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics PODD

Company Profile PODD

Business Description

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 150,000 insulin-dependent diabetics are using it worldwide.

100 Nagog Park
Acton, MA, 01720
T +1 978 600-7000
Industry Medical Devices
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Stock Type Aggressive Growth
Employees 2,300